Liposome formulation in cancer immunotherapy and challenges on early-stage development

Tuesday, October 18, 2022

12:30 PM – 1:15 PM ET

Location:Spotlight Stage 3, Exhibit Hall A&B

Presented By FUJIFILM Pharm.

Chalk Talk Presenter(s)

Naoki Yamada, MS

Director Strategy and Operation
FUJIFILM Pharmaceuticals U.S.A., Inc.
Cambridge, Massachusetts

Description: The number of clinical trials of chemotherapeutic agents (chemo) in combination with Immune Checkpoint Inhibitor (ICI) is remarkably growing to improve anti-tumor effects. In this session, we will share preclinical results that liposome formulations can boost synergistic effect of chemo with ICI by stimulating cancer immunity. In addition, the challenges on early-stage development from bench top to the 1st in human of liposome formulations: species difference and CMC, and solutions will be presented and discussed.

Learning Objectives:

To understand the emerging potential of liposome formulation in cancer immunotherapy
To understand the challenges in early-stage development of liposome formulation
To understand how to avoid any development challenges by utilizing established technologies